moderna vaccin compani increas price
lead develop mrna vaccin candid current
develop messeng rna offer sever advantag includ speed design
manufactur convent vaccin approach importantli nih began
dose phase studi novel coronaviru vaccin
yesterday preliminari data summer could enabl initi larger
potenti registr trial fall gener phase proof-of-concept data
cmv vaccin report phase ii data set-up phase
trial start next year host vaccin day april reiter
overweight rate increas price target increas vaccin
nih begin coronavir vaccin studi program highlight
mrna infrastructur speed work better coronaviru vaccin
ship first vial nih day yesterday nih dose
first subject phase healthi volunt studi assess
safeti immunogen studi random healthi adult two-dos
either administ day apart
primari endpoint safeti reactogen secondari endpoint measur
immunogen protein believ nih could get
preliminari safeti immunogen data summer may abl
begin larger potenti registr trial fall
phase ii cmv vaccin data phase ii studi enrol seroneg
seroposit healthi volunt receiv
expect data inform phase dose select start next year fda
type meet indic prevent infect women childbear age
could support registr manag guid could cost million
approv vaccin cmv lead caus birth defect
develop world project global sale billion
vaccin infecti diseas unmet medic need next decad
believ premium price vaccin merck
gardasil appropri comp estim could achiev cumul
prophylact vaccin revenu includ merck royalti elderli rsv vaccin
billion importantli revenu would recur
provid high oper margin even appli standard multipl vaccin
revenu would equat futur project valu billion decad
mrna therapeut novel could fail clinic gain approv
drug may reach sale forecast compani may invest project
develop innov mrna medicin
proj ev cash
piper sandler seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
expect signific valu creation moderna vaccin
lead develop mrna medicin compani invest heavili rna
scienc oligonucleotid chemistri bioinformat deliveri manufactur
advanc piplein mrna vaccin therapi develop financ
invest hold pro forma cash billion along industri lead partnership
merck astrazeneca azn overweight
largest therapeut area prophylact infecti diseas vaccin eight activ
program date vaccin safe administ subject
dose schedul host vaccin day april highlight
mrna technolog pipelin advanc potenti announc new vaccin candid
importantli collabor nih coalit epidem prepared
innov cepi develop novel coronaviru
believ abil rapidli develop manufactur vaccin candid highlight advantag
mrna technolog abl design manufacutr ship first vial
nih day sequenc select yesterday nih dose first healthi
volunt phase studi studi enrol healthi adult receiv
two dose twenty-eight day apart primari endpoint
safeti reactogen secondari endpoint immunogen spike
protein believ nih could get preliminari safeti immunogen data summer
posit could begin larger potenti regist trial fall
last fall report clinic proof-of-concept data wholly-own cytomegaloviru cmv
vaccin interim phase data show encod multipl cmv protein
induc high neutral antibodi titr potenti complet immun believ
result build sever posit phase studi broadli valid infecti
diseas vaccin pipelin enrol phase ii dose-confirm studi
expect report interim data base result intend initi
phase trial women childbera age approv vaccin cmv
lead caus birth defect develop world project blockbust
potenti global sale billion
develop wholly-own multi-antigen vaccin encod viral
protein associ human metapneumoviru hmpv human parainfluenza hpiv
conduct phase dose-escal dose-select studi total
healthi adult interim analysi show neutral antibodi titer hmpv
baselin one month singl vaccin clean safeti
conduct phase ib studi children data possibl
year approv vaccin lead
caus respiratori infect children year project global sale
billion recent announc pediatr rsv vaccin could
enter clinic later year
also announc new preclin vaccin candid epstein-barr
viru ebv primari caus infecti mononucleosi increas risk
lymphoprolif disord cancer multipl sclerosi current effect
vaccin ebv repres blockbust potenti
partner merck conduct phase studi second-gener potent rsv vaccin
phase studi elderli subject data like year believ
advantag mrna technolog could help merck succeed other
fail merck commerci global sale elderli project reach
billion pay mid-singl low-teen percentag royalti
page
could launch sever first-in-class prophylact vaccin infecti diseas
unmet medic need next decad believ premium price vaccin pfizer
merck gardasil hpv offer comp vaccin
depend phase data regulatori path novel coronaviru
could first vaccin receiv licensur
current project sale see potenti signific stockpil govern
affect pandem anticip could launch cmv vaccin mrna-
potenti season influenza vaccin
anticip pediatr vaccin rsv
well merck rsv vaccin could launch due
number size novel vaccin market estim could achiev cumul
prophylact vaccin revenu includ merck royalti million
billion grow billion pleas see exhibit importantli
revenu would recur provid high oper margin even appli
standard multipl vaccin revenu would equat futur project valu
billion decad
piper sandler compani estim
page
initi larger potenti registr trial vaccin fall
file ind ebv vaccin candid
file ind pediatr rsv vaccin candid
initi phase immun studi women childbear age
nih begun phase studi vaccin healthi volunt
schedul host vaccin day april
nih potenti report phase data summer
report interim analysi phase ii studi cmv vaccin
complet phase ib pediatr immun studi vaccin
merck report phase data rsv vaccin healthi elderli subject
reiter overweight rate howev increas price target
increas valu prophylact vaccin pipelin new price target base
increas project enterpris valu billion billion
continu valu wholly-own cmv vaccin million appli
standard multipl sale billion discount back
continu valu wholly-own vaccin million appli
multipl sale billion discount back view
discount rate appropri phase ii vaccin candid appropri
continu valu merck-partn rsv vaccin million appli
multipl royalti million discount back view
multipl appropri higher margin royalti discount rate appropri
today increas valu new vaccin novel coronaviru sars-
million million base nih initi phase studi
potenti meaning stockpil addit increas valu newli
announc preclin vaccin candid rsv children
epstein-barr viru million million continu add
million influenza vaccin zika vaccin
chikungunya vaccin chikungunya antibodi
valuat methodolog rest pipelin remain unchang
end cash billion subsequ issu million
share rais gross proce million estim hold pro forma
cash billion million share outstand continu add estim
net cash billion divid project market cap billion
million share arriv new price target pleas see exhibit
page
page
need new
mrna infecti diseas vaccin readi prime time
long ago vaccin industri declin hamper long develop time line high
cost product tight fda regul low profit margin result larg pharma exit
space howev last two decad innov new vaccin target increas
global demand led resurg vaccin develop accord miloud kaddar
senior advis health economist vaccin industri grown annual
past two decad twice compound-annual-growth-rate pharmaceut indsutri whole
last year vaccin among top four therapeut area revenu global sale
exceed billion glaxosmithklin gsk merck sanofi sni largest
global vaccin manufactur cumul sale billion domin industri
within compani pipelin vaccin repres largest revenu contributor
gsk leader three vaccin bexsero/menveo mening shingrix shingl
fluarix/flulav influenza compris major global vaccin sale billion
billion merck follow vaccin repres half compani top sell drug
last year merck gardasil hpv pneumovax pneumococc
proquad/mmr/varivax measl mump rubella varicella gener sale billion
world-wide merck receiv fda european approv ervebo vaccin ebola
decemb approv african countri expect near-term four vaccin
product global sale billion driven almost exclus
pneumococc bacteria actual remain compani best-sel drug sanofi vaccin
pipelin saw global sale billion billion driven influenza vaccin includ
four pharma compani continu see vaccin sale growth howev pharma
remain focus profit vaccin innov stall except respons major outbreak
like ebola coronaviru pandem novel vaccin program champion
emerg biotech compani major vaccin undifferenti
current market becom clear vaccin technolog bottleneck futur
growth innov could address issu believ leav enorm
opportun vaccin develop use next gener technolog
major vaccin market induc protect immun introduc piec
viru bodi either weaken form virul microorgan inactiv live
attenu agent fragment viral protein huge success tame even
eradict mani infecti diseas includ polio measl smallpox vaccin
approach face limit accord nation institut allergi infecti
diseas niaid convent vaccin typic take year develop preclin
commerci product et al jama vaccin
biolog iter optim process move quickli grown
also note vaccin inher riski modal higher bar safeti
given healthi subject eventu end product requir long manufactur time scale
expens combat viral outbreak zika novel coronaviru sars-
rapid deploy larg scale critic simpli feasibl convent
page
global outbreak infecti diseas id rise number well genotyp
divers particular zoonot origin increasingli common human-specif
ill becom easili transmiss person-to-person insect smith
respiratori syndrom sar middl east respiratori syndrom mer
influenza none compar current novel coronaviru sars-cov-
pandem addit convent vaccin unabl provid comprehens protect
virus frequent recurr infect respiratori syncyti viru rsv
involv complex viral protein cytomegaloviru cmv even trickier virus
success evad immun system
cost associ elong vaccin develop timelin also prohibit coalit
epidem prepared innov cepi establish support develop
vaccin epidem id commit invest least billion novel vaccin
larg phase ii/iii vaccin trial requir approv almost imposs fund unless
epidem on-going time develop cepi aim use fund encourag just-
in-cas research enabl id prepared bride gap preclin late-stag
test advanc outbreak research whose econom analys support genesi
cepi estim cost progress least one vaccin candid end phase iia
test prioriti id would cost billion cost individu id
vari wide sar command higher develop cost rang million
econom analysi reveal cost advanc vaccin candid phase ii/iii studi
order cancer drug develop howev road profit vaccin much
longer oncolog orphan diseas drug sever challeng also uniqu
vaccin develop exampl regulatori requir like prequalif licensur
countri use qa/qc requir cost driver also requir staff specif
skillset respond regulatori requir vaccin adopt low-incom countri
may requir invest appropri equip labor may push profit
profit ever gener despit valu public health failur manufactur
achiev sustain return vaccin thwart develop
messeng rna mrna develop emerg vaccin technolog sinc
earli howev time mrna technolog immatur concern around
immunogen ineffici deliveri instabl shift field toward dna-bas
protein-bas approach major advanc last two decad address issu
prepar mrna therapeut applic mrna modifi suppress
system immunogen present compar safer profil convent vaccin
compar dna-bas vaccin mrna inher infecti carri risk
mutat insert enhanc biodegrad mrna could also offer
comprehens protect accur replic assembl complex viral protein
abil rapdili design scale mrna cost effici manner distinguish
approach vaccin especi time public health threat pandem
sequenc emerg viru known inform program synthes
therapeut mrna cell-fre system design mrna vaccin new viru simpli
requir insert mrna sequenc safe establish deliveri vehicl akin
chang tape cassett process make design novel preclin mrna candid
feasibl week process also scale cost-effici manufactur larg quantiti
mrna develop
page
manufactur transform potenti
believ moderna mrna platform ideal suit design product prophylact
vaccin especi emerg viral outbreak pandem current
develop vaccin multipl infecti diseas prophylact vaccin moderna
largest therapeut modal believ repres lower technic hurdl
inher mrna properti facilit vaccin design manufactur prophylact
vaccin safeti administ subject dose level
section highlight two case studi cmv vaccin
vaccin believ case studi illustr novel properti mrna
capac compani norwood manufactur site support divers applic
prophylact vaccin phase test commerci launch well rapid design
candid address global pandem
open state-of-the-art mrna manufactur plant norwood
facil capabl produc mrna candid preclin toxicolog
studi well current manufactur practic cgmp grade drug clinic test
site transform mrna develop manufactur unpreced design
scale novel mrna vaccin lower cost
norwood contain three differ manufactur engin specif tailor produc preclin
person cancer vaccin pcv clinic mrna therapi preclin engin make
mrna batch milligram mg level date manufactur
batch preclin test norwood process complet autom allow
scientist request mrna sequenc bench via app receiv batch within
week make preclin test candid select streamlin effici
second engin pcv current yield one batch per patient scale sever hundr
milligram date pcv batch manufactur on-going phase ii
studi third clinic engin differenti manufactur capabl
abil scale mrna clinic batch gram suffici drug suppli compani first
phase trial cmv vaccin start next year larger volum possibl
clinic requir point
manufactur cmv vaccin offer case studi show mrna
uniqu adapt overcom challeng associ design scale first moderna
hypothes design vaccin requir express viral glycoprotein gb addit
pentamer complex pc effect immunogen achiev
cmv vaccin approach abil program rapidli produc mrna facilit
design preclin test scale quantiti product clinic trial
second challeng requir stabl refriger frozen condit
led develop first lyophil product compani platform within one year
enabl scale gram batch result cost reduct per mg
sinc open norwood pleas exhibit success manufactur
prepar scale batch million dose per year
page
reduct manufactur
second case studi highlight speed mrna technolog
manufactur respond unexpect pandem converg capabl
enabl first compani ship novel vaccin
within day concept januari access amino acid
sequenc design plasmid templat produc mrna day optim
amino acid sequenc design plasmid dna templat mrna product
day aggreg document requir make clinic batch mrna
accompani lipid nanoparticl lnp normal process take week month
digit autom system expedit clinic product point need
wait requir week complet steril test februari day
select amino acid sequenc ship vaccin nation
institut nih began clinic test yesterday march pleas see exhibit
timelin vaccin develop day
page
urgent need
vaccin
need effect coronaviru vaccin therapi paramount coronavirus cov
part famili single-strand rna virus gener thought origin bat cov
transmiss human via droplet airborn particl caus sever respiratori distress
result death cov caus two prior large-scal outbreak sever acut
respiratori syndrom sar middl east respiratori syndrom mer decemb
novel coronaviru origin wuhan capit hubei provinc
china caus outbreak pneumonia case unknown caus design
viru result infecti diseas
character outbreak global pandem accord john hopkin
case tracker global confirm case infect result
death fatal rate rang pandem
significantli wider spread fatal sar outbreak pleas see exhibit
comparison coronaviru infect
adapt updat confer retrovirus opportunist infect croi march
accord genom sequenc result novel coronaviru share sequenc
ident origin sars-cov nearli ident bat coronaviru zhou et al natur
homolog yield potenti target vaccin drug
develop viral spike protein previous identifi antigen vaccin
sar mer part homotrimer complex spike protein cover surfac
viral particl like crown spike origin name coronaviru enter host cell
angiotensin-convert enzym receptor known cell receptor
sars-cov li et al natur zhou et al show abl use
protein deriv human coronavirus-harbor chines horsesho bat enter
cell howev infect cell express
suggest receptor may mechan viru enter cell zhou et al
also show use coronaviru receptor aminopeptidas
apn dipeptidyl peptidas enter cell
express lung heart kidney intestin involv regul
vasoconstrict blood pressur hypertens common sever
patient suggest ace inhibitor may possibl treatment howev zhou et al note
spike protein gene longer sars-cov suggest potenti
differ spike bind domain thu novel drug specif target sars-
page
vaccin
develop
sinc outbreak drug develop commun mobil quickli begin
work therapi vaccin recent report trial sars-cov-
underway develop new small molecul antivir biolog
biocenturi note biocenturi list includ repurpos therapi test
advanc repurpos small molecul gilead remdesivir
target polymeras conserv across coronavirus includ sar remdesivir
origin develop ebola viru later test single-strand rna
virus includ sars-cov mers-cov show preclin activ sheahan et al
transl gilead nih china-japan friendship hospit
current conduct five phase ii phase clinic trial china hubei
provinc phase trial china enrol mild/moder patient sever
patient meantim case studi remdesivir-tr patient
demonstr preliminari result case publish via nejm case via medrxiv
case unclear remdesivir treatment contribut patient recoveri patient
simultan given multipl support care agent includ antibiot steroid nsaid
biolog categor vaccin antibodi
current repres largest therapeut develop effort antibodi
design block viral protein spike protein associ induc
immun antibodi also harvest recov patient develop
immun ivig therapi antibodi roch actemra tocilizumab
regeneron kevzara sarilumab investig limit cytokin releas
caus acut respiratori distress syndrom ard vaccin convent approach
protein-bas live attenu agent weaken viru form pursu along
newer rna/dna-bas vaccin approach rnai peptid even cell therapi also
attempt
earli evalu approach effect
treat seriou concern exhibit season like influenza
could spread throughout southern hemispher winter month remerg northern
hemispher fall govern cdc vaccin drug develop aim
prepar worst case scenario
scenario without preced draw global influenza pandem
also known spanish flu outbreak one wors pandem histori
estim human earth infect caus mani million death niall
et al bull hist viru spread three wave becom wors
time origin hard pin first sight theoriz begin march
 europ first wave viru contagi highli
virul circul throughout trench world war turn global outbreak
may/jun summer influenza slow howev reemerg
deadli second wave august third wave began winter
final reced summer global pandem resolv viru
continu circul year
enough inform yet predict exhibit season fact past
outbreak cov cousin mer sar paint complic pictur sar
outbreak start late last novemb juli mer outbreak began
septemb hot climat saudi arabia eventu spread warm climat
countri iran unit arab emir contain procedur help stop spread
sar mer howev neither virus contagi
page
said studi suggest warmer climat particularli high humid
gener help slow infect rate lowen et al plo lowen et al studi
guinea pig demonstr warm temperatur high humid air act
makeshift filter catch airborn virus carri water droplet prevent
travel far compar colder drier air howev epidemiologist note
mean complet disappear rate spread hope slow
mani expert believ similar coronavirus difficult control
respiratori virus like becom endem wu et al lancet
word live go forward could caus futur outbreak
across world similar ebola viru first appear reappear
remain on-going democrat republ congo
therefor therapi believ vaccin offer
best long-term solut neutral antibodi antivir stop gap measur treat
alreadi infect patient like endem coronavirus best treatment option
prevent strategi widespread vaccin mani convent vaccin
develop approach proven effect therefor
highest probabl success chanc develop time
combat current pandem fastest convent vaccin take least
sever month produc enough materi clinic trial
first compani ship vaccin nih clinic
test nih dose first healthi volunt phase studi
yeasterday nih gener preliminari safeti immunogen data summer
could begin larger potenti registr trial fall
leader develop mrna vaccin current eight program
develop believ prophylact id vaccin repres lower technic risk moderna
inher mrna properti facilit drug design manufactur moderna
prophylact vaccin demonstr safeti healthi volunt dose level
vaccin elicit function neutral antibodi viral antigen
recent anounc vaccin ship
nih day clinic tiral initi day illustr rapidli mrna
vaccin deploy pandem advanc prophylat program
wholly-own cmv vaccin report posit phase data septemb
current phase ii dose-optimz styd data due base
earli success broaden id pipelin announc addit new vaccin
candid includ epstein-barr viru ebv pediatr rsv vaccin
host vaccin day april may post-pon
webcast due current pandem expect compani provid
updat vaccin pipelin potenti announc addit new candid
page
vaccin
phase studi
collabor nih cepi develop vaccin
exist collabor vaccin research center vrc nih design
mrna encod spike protein mer repurpos
vaccin target pre-complex spike protein preclin studi
show potenti mrna vaccin induc suffici neutral antibodi reduc mer viral
load nose bronchoalveolar lavag lower limit
detect throat rabbit model pleas see exhibit
mrna vaccin spike protein boost neutral titer mer
need greatest
nih dose first subject phase studi enrol healthi
volunt evalu intramuscular inject day
day primari object studi assess safeti two vaccin dose
immunogen evalu elisa assay day
place preliminari data readout earli summer mayb earli june exact
develop path uncertain phase ii studi requir may conduct
southern hemispher summer could begin phase trial
countri northern hemispher fall base timelin would anticip
licensur potenti stockpil could potenti occur soon next year
cytomegaloviru cmv member herpesvirida famili includ hsv
ebv zoster viru cmv larg double-strand dna viru compris gene
major adult world-wide infect cmv healthi individu typic
asymptomat easili clear infect except case weaken immun system
howev cmv particularli devast fetu suscept matern utero
infect cmv infect affect neurolog develop lead signific morbid
even death approxim american women childbear age may cmv
seroposit studi conduct cdc report annual seroconvers rate
pregnant women increas daycar worker parent
american newborn infect cmv exhibit birth defect
common hear loss infect infant although long-term neurodevelopment
condit also occur includ seizur cerebr palsi microcephali learn
disabl screen routin part variabl diagnost test
lack approv cmv vaccin despit initi promis ivig work antivir drug
toxic fetu reason develop cmv vaccin high prioriti
page
advantag
modal cmv
plan
prior clinic result indic multipl cmv protein need incorpor effect
vaccin envelop glycoprotein gb pass et al nejm well
five protein form pentamer complex pc fulli form pc requir train
bodi gener correspond neutral antibodi difficult construct
suffici quantiti human use
prior attempt also fail due fact natur immun complet protect
congenit cmv transmiss mrna hold promis abil express one
epitop surfac cell induc immun mimick infect cell secondli
immun mrna extend durabl achiev tradit subunit vector dna
vaccin mrna express gb pc epitop necessari prevent viral
infect fibroblast epitheli cell respect
multi-antigen mrna vaccin encod gb five protein
form pc encapsul lnp conduct phase dose-escal studi
healthi volunt studi random cmv uninfect
seroneg well previous infect seroposit subject receiv
placebo three immun day
januari report second interim analysi final vaccin
first three dose level month dose-depend antibodi titer gener
gb pc epitop signific activ perspect also
indic proper assembl pentam complex protein seroneg
patient produc titer higher epitheli cell
higher fibroblast cell rel cmv seroposit baselin pleas see exhibit
seroposit subject saw expectedli higher fold boost epitheli cell titer
time fibroblast baselin expect titer level confer
congenit protect cmv data also show dose-depend increas
titer month believ lower dose provid suffici protect
page
mild transient flu-lik symptom common across dose cohort saw
decreas incid follow post vaccin drug relat sae observ
note one report grade elev partial thromboplastin time ptt elev
baselin self-resolv
conduct phase ii studi determin phase dose studi
assess placebo cmv seroneg
seroposit healthi volunt studi dose approxim subject
anticip interim data prepar phase trial underway could start
fda type meet indic prevent cmv infect women
childbear age could support registr blockbust potenti
present anticip approv women childbear age year
 europ assum price slight discount
europ project sale million million grow
billion europ project sale million million
grow billion equat global sale million million
grow billion pleas see exhibit
metapneumoviru hmpv respiratori viru commonli infect children
age year symptom similar common cold includ nasal congest
cough sore throat headach fever typic symptom resolv
immuno-compromis patient infant elderli risk sever lower respiratori tract
infect hmpv lead caus acut respiratori infect children
elderli individu year develop lower respiratori tract infect similar
rsv pneumonia approv treatment indic hmpv infect
typic manag fever medic
human parainfluenza hpiv virus caus rang respiratori ill children even
requir hospit parainfluenza viru common type hpiv infect
children year age often associ bronchiol bronchiti
pneumonia fact infect second common caus seriou acut respiratori
infect young children rsv caus estim
hospit annual adult build immun toler prior infect becom
re-infect current specif antivir treatment vaccin hpiv
multi-antigen vaccin encod viral protein associ hmpv
small percentag children immuno-compromis adult virus
present co-infect rational exist design prophylact vaccin virus
page
unit women child bear per cmv sale women child bear per cmv sale cmv sale
design singl vaccin compris two mrna sequenc
encod full-length protein viru protect level neutral antibodi
observ mous nhp preclin studi
conduct phase dose-escal dose-select studi
studi enrol healthi adult receiv two infus vaccin four
dose-escal cohort interim analysi show neutral antibodi titer hmpv
baselin one month singl vaccin
increas follow second vaccin sae report inject site pain
common ae grade ae conduct phase ib studi mrna-
children data possibl year
present anticip approv europ
assum price slight discount europ project sale
million grow billion europ project sale million
grow million equat global sale million
billion billion pleas see exhibit
respiratori syncyti viru rsv preval season infect caus respiratori tract
infect rsv common caus lower respiratori tract infect children global
account infect patient age resch et al vaccin
immunoth rsv also affect elderli estim
hospit american death annual accord cdc rsv season
extend month peak late decemb mid-februari
synagi palivizumab fda-approv therapi prevent rsv high-risk infant
synagi monoclon antibodi rsv fusion protein develop
medimmun approv base statist signific lower rsv hospit
treat subject versu placebo arm pediatr
howev five monthli intramuscular inject burdensom physician
wide question cost-benefit synagi per cours treatment synagi
approv older children adult avail rsv therapi
page
encod stabil pre-fusogen protein f-protein
highli conserv critic viru abil infect cell substanti structur chang
f-protein occur throughout infect target pre-fusogen epitop may elicit
phase studi first-gener healthi adult subject met endpoint
safeti toler show neutral antibodi titer rsv healthi
volunt part assess three dose level younger subject year part
evalu four dose level older subject year three dose induc
neutral antibodi titer rsv rsv younger adult first two cohort
older adult show dose-depend induct neutral titer respons appear durabl
pleas see exhibit compet antibodi titer rsv prefus protein also
observ dose-depend manner first two cohort younger older subject
well-toler dose level popul fourth dose level older
adult least toler drug-rel sae discontinu
produc neutral antibodi titer rsv phase studi
merck focus develop second-gener
season vaccin rsv elderli use merck proprietari lnp
shown superior efficaci preclin model merck halt
develop on-going phase studi data like year
rsv awar grow cdc advisori committe immun practic acip
establish rsv work group may acip make offici recommend
vaccin recommend may boost vaccin rate facilit adopt
merck commerci global pay mid-singl low-teen
percentag royalti present anticip approv
europ assum price discount europ time
approv anticip penetr reach modest europ
project merck achiev sale million billion
grow billion europ project sale million million
grow billion equat global sale million
billion billion estim could receiv royalti revenu
million million million pleas see exhibit
page
recent announc new wholly-own rsv vaccin children
year old like also encod prefus
protein howev contain differ protein sequenc formul moderna
proprietari lnp preclin mice studi shown better immunogen
respons pleas see exhibit intend conduct phase
dose escal studi healthi adult subsequ rsv-seroposit children depend
data eventu intend combin vaccin mrna-
broadli immun common respiratori virus affect children
permiss merck agreement
induc greater immunogen respons mice
page
unit elderli popul american yr get percent elderli per elderli sale europ elderli popul european get percent elderli immunizations- per elderli sale ww elderli sale royalti royalti ebv vaccin
epstein-barr viru ebv common herp viru affect nearli adult
infect children typic asymptomat ebv primari caus infecti
mononucleosi im increas risk lymphoprolif disord cancer
multipl sclerosi recent epidemiolog data show ebv seroneg student
enter colleg seroconvert develop im symptom fatigu
often persist month estim case cancer world-wide associ
ebv includ gastric nasopharyng carcinoma burkitt hodgkin lymphoma
ebv infect propag epitheli cell cell ebv protein enabl entri
host cell epitheli cell viral envelop protein gb viral glycoprotein
complex gh gl gh/gl gb core viral protein conserv among herp
virus wherea uniqu ebv approv vaccin
ebv major ebv vaccin clinic target vaccin
demonstr im reduct phase ii studi healthi volunt protect
seen asymptomat ebv infect cell infect block leav epitheli
cell open infect studi shown effect ebv vaccin may requir neutral
antibodi product five ebv protein provid comprehens immun
recent announc develop ebv vaccin consist
mrna encod viral complex gh gl gpb formul
proprietari lnp preclin studi mice nhp reveal induct antigen-specif
antibodi cell epitheli cell infect plan conduct phase studi
prevent ebv mononucleosi post-ebv seroneg adult
risk associ common drug discovery/develop compani
includ clinic regulatori commerci vaccin cancer orphan diseas
cardiovascular diseas competit field mrna novel technolog limit clinic
experi approv therapi vaccin therapi may fail clinic
gain regulatori approv increas polit pressur reimburs push back
may challeng premium price mrna therapi mrna drug may achiev
sale forecast may invest project compani exist
partnership may falter unabl sign new collabor may unabl file
new ind advanc mrna candid clinic may requir addit capit
could face futur litig
rate overweight price target base non-gaap
dilut ep discount risk cf drug may fail clinic gain approv
may meet expect
page
thousand except per share data
compani report piper sandler estim
current disclosur inform compani found
